Loading organizations...

§ Venture Capital · Tel Aviv, Israel
Publicly traded venture fund invests in clinical-stage healthtech, focusing on medical devices, digital health, bioconvergence.
Founded in 2020 by Irit Yaniv, Amir Blatt, and Tzahi Sultan, Almeda Ventures is a publicly traded healthtech venture fund in Tel Aviv, Israel. Operating as a limited partnership on the Tel Aviv Stock Exchange, the firm invests in clinical stage medical device, digital health, and bioconvergence companies. The organization targets post proof of concept startups to finance clinical trials for FDA approval and initial sales, aiming for exits within five years. During its initial public offering, the fund raised 69 million Israeli new shekels, equivalent to approximately $20 million, in a round oversubscribed by 3.7 times. The active portfolio features investments like $3 million in BioProtect and $1 million in TailorMed, alongside equity in Upstream Bio, and the fund jointly led a $13 million funding round for FlexDex alongside Johnson and Johnson Innovation.
Key people at Almeda Ventures.
Almeda Ventures is a venture capital firm specializing in health technology investments, with a focus on medical devices, digital health, and bio-convergence. Founded in 2020 and based in Tel Aviv, Israel, the firm invests globally, primarily targeting startups and companies in Israel, the USA, and Europe. Its mission centers on advancing innovative healthtech solutions through public R&D partnerships, supporting companies from seed stage through early venture and middle market phases. Almeda Ventures plays a significant role in the startup ecosystem by fueling innovation in healthcare, particularly in areas that combine technology with life sciences to improve patient outcomes and healthcare delivery[1][2][4].
Almeda Ventures was founded in 2020 by key partners including Amir David Blatt (Founding Partner and CEO) and Yitzhak Menachem Sultan (Founding Partner and Director). The firm emerged to address the growing need for specialized investment in health technology sectors, leveraging expertise in both venture capital and medical innovation. Over time, it has evolved to emphasize public R&D partnerships, enabling collaboration between startups and research institutions. The leadership team includes experienced professionals and medical advisors, which strengthens its ability to identify and nurture promising healthtech ventures[1][3][4].
Almeda Ventures is riding the wave of digital transformation in healthcare, a trend driven by increasing demand for personalized, efficient, and technology-enabled medical solutions. The timing is critical as healthcare systems worldwide seek innovations that reduce costs and improve outcomes, especially in medical devices and digital health platforms. Market forces such as aging populations, chronic disease prevalence, and advances in biotechnology favor Almeda’s investment focus. By fostering early-stage companies in these sectors, Almeda Ventures influences the broader ecosystem by accelerating the commercialization of cutting-edge health technologies and bridging gaps between research and market adoption[1][2][4].
Looking ahead, Almeda Ventures is poised to expand its global footprint and deepen its impact in healthtech innovation. Trends such as AI integration in medical devices, telehealth expansion, and bio-convergence technologies will likely shape its investment strategy. The firm’s unique public R&D partnership model positions it well to capitalize on collaborative innovation, potentially increasing its influence in shaping next-generation healthcare solutions. As health technology continues to evolve rapidly, Almeda Ventures’ role as a specialized investor and ecosystem enabler will likely grow, making it a key player in the future of digital health and medical innovation[1][4].
Key people at Almeda Ventures.
Almeda Ventures has 2 tracked investments across 2 companies. The latest tracked deal is $82.5M Series D in Augmedics in June 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 27, 2023 | Augmedics | $82.5M Series D | Cpmg | Paul Enever, H.I.G. Capital, Revival Healthcare Capital |
| Dec 1, 2021 | Clanz Technologies | $14.0M Series A | Entrée Capital Ventures | Giza Polish Ventures, Insight Partners, Matias Ventures, MoreVC, Pitango Venture Capital, Yossi Matias, Flint Capital, Homeward Ventures, Jibe Ventures, Operator Partners |